Difference between revisions of "AM-679 (cannabinoid)"

From Wiki Weed
Jump to: navigation, search
(Created page with "AM-679 is a drug that acts as a moderately potent agonist for the cannabinoid receptors, with a Ki of 13.5nM at CB1 and 49.5nM at CB2. AM-679 was one of the first...")
 
 
Line 1: Line 1:
[[AM-679]] is a drug that acts as a moderately potent agonist for the cannabinoid receptors, with a Ki of 13.5nM at [[CB1]] and 49.5nM at [[CB2]]. AM-679 was one of the first 3-(2-iodobenzoyl)indole derivatives that was found to have significant cannabinoid receptor affinity, and while AM-679 itself has only modest affinity for these receptors, it was subsequently used as a base to develop several more specialised [[cannabinoid]] ligands that are now widely used in research, including the potent CB1 agonists [[AM-694]] and [[AM-2233]], and the selective CB2 agonist [[AM-1241]]. AM-679 was first identified as having been sold as a cannabinoid designer drug in Hungary in 2011, along with another novel compound 1-pentyl-3-(1-adamantoyl)indole.
+
'''AM-679''' is a drug that acts as a moderately potent agonist for the cannabinoid receptors, with a Ki of 13.5nM at [[CB1]] and 49.5nM at [[CB2]]. AM-679 was one of the first 3-(2-iodobenzoyl)indole derivatives that was found to have significant cannabinoid receptor affinity, and while AM-679 itself has only modest affinity for these receptors, it was subsequently used as a base to develop several more specialised [[cannabinoid]] ligands that are now widely used in research, including the potent CB1 agonists [[AM-694]] and [[AM-2233]], and the selective CB2 agonist [[AM-1241]]. AM-679 was first identified as having been sold as a cannabinoid designer drug in Hungary in 2011, along with another novel compound 1-pentyl-3-(1-adamantoyl)indole.
  
  

Latest revision as of 16:27, 14 February 2015

AM-679 is a drug that acts as a moderately potent agonist for the cannabinoid receptors, with a Ki of 13.5nM at CB1 and 49.5nM at CB2. AM-679 was one of the first 3-(2-iodobenzoyl)indole derivatives that was found to have significant cannabinoid receptor affinity, and while AM-679 itself has only modest affinity for these receptors, it was subsequently used as a base to develop several more specialised cannabinoid ligands that are now widely used in research, including the potent CB1 agonists AM-694 and AM-2233, and the selective CB2 agonist AM-1241. AM-679 was first identified as having been sold as a cannabinoid designer drug in Hungary in 2011, along with another novel compound 1-pentyl-3-(1-adamantoyl)indole.


See also